What are the major outcomes from the 2010?

19 out of 20 originator companies (95%) provided data about their Access to Medicine programs. In 2008, only 9 out of 17 originator companies (53%) chose to do so.
Most companies, including the top-3, have improved in their transparency, performance and commitments to access to medicine.
Compared to 2008, more companies shared intellectual property for research purposes; more research collaborations were instigated; several promising innovative approaches were pioneered, and more collaboration with generics companies were established, especially through non-exclusive voluntary licensing arrangements.
Rapid risers: Gilead Sciences (up from 15 to 4) and Pfizer (up from 17 to 11).
Lower rankings for Novo Nordisk (down from 2 to 7), Bayer (down from 9 to 14), Bristol-Myers Squibb (down from 11 to 15), Merck KGaA (down from 13 to 17). For Novo Nordisk, there were significant changes in the Index methodology itself.
The top-10 of originator companies includes six companies based in Europe and four based in the United States. In 2008, seven companies in the top-10 were based in Europe.

The Index